A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to Severe Chronic Obstructive Pulmonary Disease. The study consists of a screening period of up to 4 weeks, a randomized treatment period of 24 to 52 weeks, and a 12-week safety follow-up period.

NCT Number	NCT07418736
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	Chronic Obstructive Pulmonary Disease
Enrollment	318 participants
Start Date	2025-12-18
Primary Completion	2027-07-01 (estimated)
Study Completion	2027-10-10 (estimated)
Updated on ClinicalTrials.gov	2026-02-18